Download PDF
Thromb Haemost 1992; 67(01): 050-055
DOI: 10.1055/s-0038-1648378
Original Articles
Schattauer GmbH Stuttgart

Modulation of Protein C Inhibitor Activity by Histidine-Rich Glycoprotein and Platelet Factor 4: Role of Zinc and Calcium Ions in the Heparin-Neutralizing Ability of Histidine-Rich Glycoprotein

Yoshiaki Kazama
The Department of Biochemistry Niigata, University School of Medicine, Niigata, Japan
,
Takehiko Koide
The Department of Biochemistry Niigata, University School of Medicine, Niigata, Japan
› Author Affiliations
Further Information

Publication History

Received 18 July 1990

Accepted after revision 25 July 1991

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Effects of zinc and calcium ions on the heparin-neutralizing abilities of histidine-rich glycoprotein (HRG) and platelet factor 4 (PF4) were examined. Both HRG and PF4 effectively neutralized the ability of heparin to accelerate the activated protein C (APC) and the thrombin inhibitions by protein C inhibitor (PCI). The heparin-neutralizing ability of HRG in the APC inhibition by PCI, however, was decreased in a Ca2+-dependent manner and apparently lost at 1 mM Ca2+, while it was enhanced by Zn2+ regardless of the presence or absence of Ca2+. The heparinneutralizing ability of HRG in the thrombin inhibition by PCI was not affected by Ca2+.In contrast to HRG, there was no significant difference in the heparin-neutralizing ability of PF4 in the presence or absence of 1 mM Ca2+. These results strongly suggest additional physiological functions of HRG and PF4 as modulators of PCI.

 

  • References

  • 1 Kisiel W. Human protein C. Isolation, characterization, and mechanism of activation by a-thrombin. J Clin Invest 1979; 64: 761-769
    CrossrefPubMedGoogle Scholar
  • 2 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168
    PubMedGoogle Scholar
  • 3 Heeb MJ, España F, Geiger M, Collen D, Stump DC, Griffin JH. Immunological identitiy of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem 1987; 262: 15813-15816
    PubMedGoogle Scholar
  • 4 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by di-antitrypsin. J Biol Chem 1988; 263: 11613-11616
    PubMedGoogle Scholar
  • 5 Suzuki K, Nishioka J, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem (Tokyo) 1984; 95: 187-195
    CrossrefPubMedGoogle Scholar
  • 6 Meijers JCM, Kanters DHAJ, Vlooswijk RAA, Erp HEV, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237
    CrossrefPubMedGoogle Scholar
  • 7 Kazama Y, Niwa M, Yamagishi R, Takahashi K, Sakuragawa N, Koide T. Specificity of sulfated polysaccharides to accelerate the inhibition of activated protein C by protein C inhibitor. Thromb Res 1987; 48: 179-185
    CrossrefPubMedGoogle Scholar
  • 8 Kazama Y, Koide T, Sakuragawa N. Further characterization of dextran sulfate as a cofactor of protein C inhibitor. Thromb Res 1989; 54: 499-504
    CrossrefPubMedGoogle Scholar
  • 9 Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1-6
    CrossrefPubMedGoogle Scholar
  • 10 Koide T. The primary structure of human histidine-rich glycoprotein and its function as a modulator of coagulation and fibrinolysis. In: Fibrinolysis: Current Prospects. Gaffney PJ, Castellino FJ, Plow EF, Takada A. (eds). John Libbey; London - Paris: 1988. pp 55-63
    Google Scholar
  • 11 Saigo K, Shatsky M, Levitt LJ, Leung LLK. Interaction of histidine-rich glycoprotein with human T lymphocytes. J Biol Chem 1989; 264: 8249-8253
    PubMedGoogle Scholar
  • 12 Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983; 258: 3803-3808
    PubMedGoogle Scholar
  • 13 Engesser L, Kluft C, Briët E, Brommer EJP. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67: 355-358
    CrossrefPubMedGoogle Scholar
  • 14 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
    CrossrefPubMedGoogle Scholar
  • 15 Tollefsen DM, Pestka CA. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. J Clin Invest 1985; 75: 496-501
    CrossrefPubMedGoogle Scholar
  • 16 Koide T, Odani S, Ono T. Human histidine-rich glycoprotein: Simultaneous purification with antithrombin III and characterization of its gross structure. J Biochem (Tokyo) 1985; 98: 1191-1200
    CrossrefPubMedGoogle Scholar
  • 17 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976; 251: 4273-4282
    PubMedGoogle Scholar
  • 18 Franza BR, Aronson DL, Finlayson JS. Activation of human prothrombin by a procoagulant fraction from the venom of Echis carinatus. Identification of a high molecular weight intermediate with thrombin activity. J Biol Chem 1975; 250: 7057-7068
    PubMedGoogle Scholar
  • 19 Heimburger N, Haupt H, Kranz T, Baudner S. Humanserumproteine mit hoher Affinität zu Carboxymethylcellulose, II. Physikalischchemische und immunologische Charakterisierung eines histidinreichen 3.8 a2-Glykoproteins (CM-Protein 1). Hoppe-Seyler Z Physiol Chem 1972; 353: 1133-1140
    PubMedGoogle Scholar
  • 20 Fenton JW, Fascos MJ, Stackrow AB. Human thrombins. Production, evaluation, and properties of a-thrombin. J Biol Chem 1977; 252: 3587-3598
    PubMedGoogle Scholar
  • 21 Koide T. Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum. J Biochem (Tokyo) 1979; 86: 1841-1850
    CrossrefPubMedGoogle Scholar
  • 22 Peterson CB, Morgan WT, Blackburn MN. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. J Biol Chem 1987; 262: 7567-7574
    PubMedGoogle Scholar
  • 23 Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-3986
    PubMedGoogle Scholar
  • 24 Niwa M, Yamagishi R, Kondo S, Sakuragawa N, Koide T. Histidine-rich glycoprotein inhibits the antithrombin activity of heparin cofactor II in the presence of heparin or dermatan sulfate. Thromb Res 1985; 37: 237-240
    CrossrefPubMedGoogle Scholar
  • 25 Walz DA, Hung G. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Semin Thromb Hemostas 1985; 11: 40-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Saito H, Goodnough LT, Boyle JM, Heimburger N. Reduced histidine-rich glycoprotein levels in plasma of patients with advanced cirrhosis. Possible implications for enhanced fibrinolysis. Am J Med 1982; 73: 179-182
    CrossrefPubMedGoogle Scholar
  • 27 Suzuki K. Activated protein C inhibitor. Semin Thromb Hemostas 1984; 10: 154-161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Owen WG, Busch G. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 1982; 69: 726-729
    CrossrefPubMedGoogle Scholar
  • 29 McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascualr smooth muscle cells. J Biol Chem 1987; 262: 169-175
    PubMedGoogle Scholar
  • 30 Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Histidine-rich glycoprotein does not interfere with interactions between antithrombin III and heparin-like compounds on vascular endothelial cells. Blood 1989; 73: 191-193
    PubMedGoogle Scholar